ArticleCancers2021
Comparison of
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Pooled it
- Delayed Salvage Radiation Therapy Guided by Contrast-Enhanced Local and Whole-Body Diffusion-Weighted Magnetic Resonance Imaging During Prostate-Specific-Antigen-Based Surveillance After Radical Prostatectomy: A Retrospective Cohort Study.Advances in radiation oncology · 2026Article
- The Role of Artificial Intelligence in Optimizing Diagnosis in Prostate Cancer-A Narrative Review.Journal of clinical medicine · 2026Review
- Biomarkers for Precision Prognosis in Prostate Cancer: Imaging, Molecular, and Integrated Approaches.Cancers · 2026Review
- ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancer.European radiology · 2026Review
- Article
- PSMA PET/CT improves precision diagnosis, treatment, and clinical decision-making in prostate cancer.American journal of translational research · 2026Review
- Article
- Impact ofDiagnostics (Basel, Switzerland) · 2025Article
- Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer.Prostate cancer and prostatic diseases · 2025Article
- Development and validation of a visual nomogram for predicting clinically significant prostate cancer in negative mpMRI usingScientific reports · 2025Article
- Performance of PSMA-PET/CT as verified by bone biopsy for diagnosing osseous metastases of prostate cancer.Skeletal radiology · 2025Article
- Therapeutic Consequences ofCancers · 2025Article
- Fluorescence-guided lymphadenectomy in robot-assisted radical prostatectomy: the role of interventional radiology.Frontiers in radiology · 2025Article
- Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment.Cancers · 2024Review
- Review
- Radiation therapy after radical surgery in prostate cancer.Ecancermedicalscience · 2023Review
- Clinical advancement of precision theranostics in prostate cancer.Frontiers in oncology · 2023Review
- The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer.Nature reviews. Urology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundProstate specific membrane antigen (PSMA) positron emission tomography computed tomography (PET-CT) and whole-body magnetic resonance imaging (WB-MRI) outperform standard imaging technology for the detection of metastasis in prostate cancer (PCa). There are few direct comparisons between both modalities. This paper compares the diagnostic accuracy of PSMA PET-CT and WB-MRI for the detection of metastasis in PCa. One hundred thirty-four patients with newly diagnosed PCa (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.